Search

Your search keyword '"Beraldi E"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Beraldi E" Remove constraint Author: "Beraldi E" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
26 results on '"Beraldi E"'

Search Results

8. <italic>Toxoplasma gondii</italic> promotes changes in VIPergic submucosal neurons, mucosal intraepithelial lymphocytes, and goblet cells during acute infection in the ileum of rats.

10. Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling.

11. Regulation of AR mRNA translation in response to acute AR pathway inhibition.

12. Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling.

13. A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma.

14. Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer.

15. A polymeric paste-drug formulation for intratumoral treatment of prostate cancer.

16. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models.

17. Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release.

18. Toxoplasma gondii promotes changes in VIPergic submucosal neurons, mucosal intraepithelial lymphocytes, and goblet cells during acute infection in the ileum of rats.

19. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

20. Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.

21. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.

22. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.

23. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.

24. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.

25. A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor.

26. Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival.

Catalog

Books, media, physical & digital resources